Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Daily Feed
  • IR Room
  • RESEARCH
  • Disclosures
    • Semiconductors
    • Energy
    • Robotics
    • Bio & Healthcare
  • Toggle search form

[Disclosure] Celltrion (068270) to List 184,080 Additional Common Shares Following Stock Option Exercises

Posted on May 15, 2026July 14, 2026 By K-STOCK Editor No Comments on [Disclosure] Celltrion (068270) to List 184,080 Additional Common Shares Following Stock Option Exercises

Fact Source: Financial Supervisory Service DART / 2026-05-15

Disclosure Type: Additional Listing (Exercise of Stock Option)

💡 3-Second Summary

Celltrion has officially announced the upcoming additional listing of 184,080 common shares on May 20, 2026, generated through the exercise of employee stock options.

📊 1. [Summary of Key Disclosure Content and Figures]

  • Class and Number of Additional Shares: Registered common stock, 184,080 shares in total
    • 179th Issuance: 15,458 shares
    • 180th Issuance: 9,736 shares
    • 181st Issuance: 20,521 shares
    • 182nd Issuance: 16,909 shares
    • 183rd Issuance: 27,278 shares
    • 184th Issuance: 15,403 shares
    • 185th Issuance: 40,567 shares
    • 186th Issuance: 7,000 shares
    • 187th Issuance: 10,082 shares
    • 188th Issuance: 21,126 shares
  • Issue Price per Share (by Issuance):
    • 179th: KRW 71,999
    • 180th: KRW 156,285
    • 181st: KRW 156,746
    • 182nd: KRW 146,601
    • 183rd: KRW 139,147
    • 184th: KRW 171,530
    • 185th: KRW 123,606
    • 186th: KRW 128,858
    • 187th: KRW 126,825
    • 188th: KRW 123,935
  • Total Capital Raised: KRW 24,580,971,795 (Approx. KRW 24.58B)
  • Date of Issuance: April 27, 2026
  • Dividend Base Date: January 1, 2026 (Fiscal year-end: End of December)
  • Method of Capital Increase: Exercise of Stock Options
  • Listing Date (Trading Commencement): May 20, 2026
  • Stock Ticker Code: 068270

📈 2. [Professional Insight: What This Disclosure Means for Investors]

  • Assessment of Floating Supply and Overhang Risk: A total of 184,080 newly issued common shares will enter the market on May 20, 2026. Because these shares are owned by corporate employees who exercised vested options, there is a potential risk of near-term profit-taking sales. Investors should monitor whether this volume causes temporary supply-side friction post-listing.
  • Negligible Shareholder Value Dilution: Given the massive scale of Celltrion’s overall equity capitalization, the newly added 184,080 common shares represent a fractional proportion of the total outstanding share float. Consequently, the fundamental dilution of per-share metrics is expected to be practically zero.
  • Analysis of Exercise Price Spreads: The option strike prices range from a low of KRW 71,999 (179th) to a high of KRW 171,530 (184th). Contracts with lower strike prices carry higher embedded gains for the employees, which may increase the potential likelihood of immediate open-market liquidation compared to contracts issued near current market values.

📝 Editor’s Comment (by K-STOCK Editor)

Celltrion’s capital base is expanding slightly as employees exercise their stock options, adding 184,080 common shares to the tradeable float on May 20. This corporate exercise channels approximately KRW 24.58 billion in cash equity back into the company’s balance sheet. While a 184k share increase is far too minor to disrupt Celltrion’s larger fundamental trend or dilute outstanding value, the wide gap between the lower KRW 71k strike prices and current trading bands implies that some immediate profit-taking flow could pass through domestic brokerages on the listing date. Global trading desks should treat this as a standard, minor liquidity event with minimal structural impact on long-term valuation models.

📢 Disclaimer & Source Information

Source: This content has been structured and newly written based on official disclosure data submitted to the Financial Supervisory Service’s Electronic Disclosure System (DART).

Investment Risk Advisory: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice, solicitation, or a recommendation to buy or sell any specific stock. All investment decisions and financial liabilities rest entirely with the individual investor.

Inquiries: For compliance queries or copyright-related requests, please contact us at ksb220805@gmail.com.

🐂
BULLS
VS
🐻
BEARS

🔥 Bulls vs Bears, drop your analysis in the comments!

Disclosures, Bio & Healthcare

Post navigation

Previous Post: [Disclosure] Hana Micron (067310) Issued ‘Investment Warning’ Prior Notice; Reclassified as Investment Caution Stock on May 18
Next Post: [Disclosure] Alteogen (196170) Scores Huge Win: Eylea Biosimilar ‘Eyzanfy’ Secures Official MFDS Marketing Approval in South Korea

Related Posts

[Disclosure] Alteogen(196170) Submits Fiscal Year Audit Report; Financial Uncertainty Resolved with ‘Unqualified’ Clean Opinions Disclosures
[Disclosure] SAMSUNG BIOLOGICS(207940) Trading Briefly Suspended and Resumed on May 22 Following Major Corporate Split Announcement Disclosures
[Disclosure] Samsung Biologics (207940) Amends European Pharma Contract Value Upward to KRW 400.7B Disclosures
[Disclosure] Samsung Biologics (207940) Extends Confidentiality Period to 2028 for KRW 144.6B CMO Contract with Asian Pharma Disclosures
[Disclosure] Samsung Biologics (207940) Wins 1st Instance Lawsuit to Cancel Disciplinary Dispositions and KRW 8B Fine by Financial Regulators Disclosures
[Disclosure] Samsung Biologics (207940) Upgrades 2024 Revenue Guidance to KRW 4.34T, Targeting Up to 20% YoY Growth Disclosures

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] Celltrion (068270) Submits Application to Modify Phase 3 Clinical Trial Plan for ‘CT-P44’ (Darzalex Biosimilar) in EuropeJuly 14, 2026
  • [Disclosure] Hanmi Semiconductor (042700) Reports Q2 2026 Operating Profit of KRW 130.3B… A Explosive 1,441.4% QoQ SurgeJuly 14, 2026
  • [Disclosure] SK Square (402340) Discloses Subsidiary SK Hynix’s Successful ADR Listing on the U.S. NASDAQ MarketJuly 13, 2026
  • [Disclosure] SK Hynix (000660) Completes Listing of ADRs (American Depositary Receipts) on the U.S. NASDAQ MarketJuly 13, 2026
  • [Disclosure] Samsung Electronics (005930) to Dispose of KRW 322.8B Worth of Treasury Shares for Executive BonusesJuly 13, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme